The Trendlines Group (SGX:42T) entered into an asset purchase agreement with Trendlines Labs to transfer its Trendlines Innovation Labs business division, according to a filing with the Singapore Exchange on Wednesday.
The purchase consideration comprises royalties from specific customer projects with a sharing structure from 25% to 75% and a revenue share of 5% of annual net revenues, which will be paid for 10 years starting from January capped at SG$2.4 million.
Under the agreement, Trendlines Labs will also have the option to acquire Trendlines Medical Shanghai Innovation Centre, Trendlines Labs Management and the business division of Trendlines Labs Singapore.
Shares of the healthcare services provider surged over 17% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。